Searchable abstracts of presentations at key conferences in endocrinology

ea0002p17 | Clinical case reports | SFE2001

High uptake of I123-Tyr3 Octreotide in the thyroid gland- the significance of hot thyroid nodules in screening for carcinoid metastases

Kos K , Lakhdar A , Hill J

A previously fit 36 year old lady presented with 3 days of pleuritic chest pain and SOB. A CxR showed consolidation at the left heart border. Following antibiotics she made a good recovery. On examination an incidental right thyroid nodule was identified. She was clinically euthyroid. FT4,FT3 were normal and TSH suppressed. The CxR a month later did not change. A CT scan revealed a 5x4cm mass in the left lower lobe, abutting the descending aorta and left atrium. Bronchoscopy r...

ea0005p63 | Clinical Case Reports | BES2003

An unusual case of thyroid enlargement in pregnancy

Kos K , Warner D , West T

A 20 years old primigravida 11weeks pregnant presented with increasing neck size, having noticed some neck swelling 4 years previously. There was no history of dysphagia or stridor. Apart of mild asthma she was well with no significant past medical or family history. TSH was normal at the time she was referred by the GP to the endocrine clinic. On examination she had a smooth thyroid swelling but no cervical lymphadenopathy. Further thyroid function tests confirmed a normal TS...

ea0011p238 | Cytokines and growth factors | ECE2006

The depot specific expression of NPY in human adipose tissue and its upregulation under hyperinsulinaemic conditions in isolated human adipocytes

Kos K , Harte AL , Gupta P , O’Hare P , McTernan PG , Kumar S

Neuropeptide Y (NPY) is a centrally expressed peptide with potent orexigenic properties, released post-prandially to stimulate appetite, regulated by insulin and altered by obesity. NPY is expressed in adipose tissue which suggests it may have a potential effect on altering appetite control in obesity. To date no study has investigated NPY and its regulation in human adipose tissue. Therefore, the aims of this study were to 1) determine the depot-specific expression in abdomin...

ea0007p156 | Neuroendocrinology and behaviour | BES2004

Metastatic glucagonoma transforming to an insulinoma

Byard A , Rangan S , Dixon A , Kos K , Edavalath M , Buch H , Singh B

Neuroendocrine tumours are uncommon and often present difficult therapeutic challenges. They may be composed of different cell types and are often multihormonal. We present the case of a 75 year-old man diagnosed to have a glucagonoma in 1995. He was deemed unfit for curative surgery and was managed medically including insulin therapy for control of hyperglycaemia. Over the next 7 years the patient became progressive more symptomatic due to increase in tumour size and hepatic ...